Australian Federation of AIDS Organisations (AFAO), 26 June 2018
There has long been concern globally about the potential emergence of drug resistant STIs. In response, the World Health Organisation released new treatment guidelines for three common STIs – chlamydia, gonorrhoea and syphilis – in 2016.
At present, strains resistant to first line treatment of syphilis and chlamydia are not common and not a concern in Australia. There is, however, a growing level of concern about gonorrhoea. This paper therefore focuses on the likelihood and implications of the emergence of drug resistant cases of gonorrhoea in Australia. It also highlights treatment options in Australia and current and emerging strategies for preventing drug resistant gonorrhoea.
Cases of a strain of gonorrhoea impervious to an antibiotic have almost tripled in six months, the latest report from the National Alert System for Critical Antimicrobial Resistance (CARAlert) reveals.
The result was a “warning shot across the bow” for doctors and public health officials fighting antibiotic resistance, CARAlert’s senior medical adviser said.
A critically drug-resistant strain of gonorrhoea dubbed a “super-superbug” has been detected in every Australian state and territory by a new national surveillance system.
The National Alert System for Critical Antimicrobial Resistance (CARAlert) identified 1,064 bacteria highly resistant to last-line antibiotics between 17 March 2016 and 31 March 2017 across 73 laboratories.
The Lancet Infectious Diseases, 17 (2), February 2017
Antimicrobial resistance in Neisseria gonorrhoeae is recognised globally as a public health threat. Dual therapy with ceftriaxone and azithromycin has been introduced in Australia and elsewhere as the first-line treatment recommendation for gonorrhoea. While there have been only sporadic reports of ceftriaxone-resistant gonococci, globally there have been increasing reports of N gonorrhoeae resistance to azithromycin.1 The Australian Gonococcal Surveillance Programme2 is one of the most comprehensive N gonorrhoeae antimicrobial resistance surveillance programmes worldwide.
For many gay and bi men, it’s a perennial point of contention: Are “minor” sexually transmitted infections—like chlamydia or gonorrhea—a cause for serious concern or major behavior modification?
A recent study by the Centers for Disease Control and Prevention, featured in its Morbidity and Mortality Weekly Report, found a significant rise in resistance to one of the drugs used to treat gonorrhea: azithromycin.
In one of the most tightly controlled trials ever conducted of drugs used to treat sexually transmitted infections, researchers at the University of Alabama at Birmingham have confirmed that azithromycin remains effective in the treatment of urogenital chlamydia.
In a study published Dec. 24 in the New England Journal of Medicine, the research team compared two of the most commonly used medications for urogenital chlamydia.